Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13593454 | 0.83 | MAPT (0.51) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL11946809 | 0.83 | KDM4E (0.51) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL31283565 | 0.82 | GPR119 (0.54) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL15376450 | 0.82 | GPR119 (0.51) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL30779438 | 0.81 | THRB (0.49) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL3460996 | 0.80 | KDM4E (0.48) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL2103880 | 0.79 | GPR119 (0.47) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL31283721 | 0.78 | THRB (0.46) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL16965440 | 0.77 | NAMPT (0.58) | MAPTKDM4ETHRBGPR119PTPN2 | |
| SCHEMBL65161 | 0.77 | LMNA (0.48) | MAPTKDM4EGPR119NAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4573092-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | Olema Pharmaceuticals, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024039860-A1 | 2,3,4,9-TETRAHYDRO-1H-PYRIDO[3,4-B]INDOLE DERIVATIVES AS ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | OLEMA PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-9603833-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2017-03-28 | — | — | US | disclosed |
| EP-2886534-A1 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-Tech Ueno, Ltd. (JP) | 2015-06-24 | — | — | EP | disclosed |
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R TECH UENO LTD (JP) | 2015-06-18 | — | — | US | disclosed |
| US-8999989-B2 | Benzene or thiophene derivative and use thereof as VAP-1 inhibitor | R-TECH UENO, LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| EP-2300430-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-Tech Ueno, Ltd. (JP) | 2011-03-30 | — | — | EP | disclosed |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2011-03-10 | — | — | US | disclosed |
| WO-2009145360-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | R-TECH UENO, LTD. (JP) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166525-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | MAPT 1522/4885KDM4E 1213/4885THRB 1296/4885 |
| US-20110059957-A1 | BENZENE OR THIOPHENE DERIVATIVE AND USE THEREOF AS VAP-1 INHIBITOR | VAPB, VAPA, BET1 | MAPT 1522/4885KDM4E 1213/4885THRB 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.